Alirocumab reduces lipoprotein(a), lowers cardiovascular risk, finds study
Among patients receiving intensive statin therapy following a recent acute coronary syndrome, patient-level reductions in lipoprotein(a) by alirocumab independently contributed to reduced risk of a first primary outcome event and first PAD or VTE event,suggests the reports of a recently published study in the European Heart Journal.
In previous studies, Elevated baseline levels of lipoprotein(a), a genetically determined low-density lipoprotein particle, have been associated with increased risk of cardiovascular events
Lipoprotein(a) concentration is associated with first cardiovascular events in clinical trials. It is unknown if this relationship holds for total (first and subsequent) events.
In the ODYSSEY OUTCOMES trial in patients with recent acute coronary syndrome (ACS),researchers assessed the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab reduced lipoprotein(a), low-density lipoprotein cholesterol (LDL-C), and cardiovascular events , compared with placebo. The trial continued until 1613 patients experienced a primary outcome event or all surviving patients (other than those enrolled in China) were eligible to be followed for at least 2 years.
The outcomes assessed were Cardiovascular events including cardiovascular death, non-fatal myocardial infarction, stroke, hospitalization for unstable angina or heart failure, ischaemia-driven coronary revascularization, peripheral artery disease events, and venous thromboembolism.
Proportional hazards models estimated relationships between baseline lipoprotein(a) and total cardiovascular events in the placebo group, effects of alirocumab treatment on total cardiovascular events by baseline lipoprotein(a), and relationships between lipoprotein(a) reduction with alirocumab and subsequent risk of total cardiovascular events.
On analysis, the following facts emerged.
- Baseline lipoprotein(a) predicted total cardiovascular events with placebo, while higher baseline lipoprotein(a) levels were associated with greater reduction in total cardiovascular events with alirocumab (hazard ratio Ptrend = 0.045).
- Alirocumab-induced reductions in lipoprotein(a) (median -5.0 [-13.6, 0] mg/ dL) and corrected LDL-C (median -51.3 [-67.1, -34.0] mg/dL) independently predicted lower risk of total cardiovascular events.
- Each 5-mg/dL reduction in lipoprotein(a) predicted a 2.5% relative reduction in cardiovascular events.
"These findings support the concept of lipoprotein(a) as a treatment target among high-risk patients with a recent acute coronary syndrome." wrote the team.
Primary source: European Heart Journal
For the full article,follow the link:
doi:10.1093/eurheartj/ehaa649
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.